眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法

2022-03-18 中国眼科相关专家组（统称） J Microbiol Immunol Infect

葡萄膜炎

葡萄膜炎是一种威胁视力的眼部疾病，可由多种不同病因引起。葡萄膜炎的成功治疗主依赖准确诊断和有效治疗。本文主要提供了葡萄膜炎患者的分步诊断建议。

中文标题：

2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法

英文标题：

Step-wise diagnostic approach for patients with uveitis - Experts consensus in Taiwan

发布机构：

中国眼科相关专家组（统称）

发布日期：

2022-03-18

简要介绍：

葡萄膜炎是一种威胁视力的眼部疾病，可由多种不同病因引起。葡萄膜炎的成功治疗主依赖准确诊断和有效治疗。本文主要提供了葡萄膜炎患者的分步诊断建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法.pdf)] GetToolGuiderByIdResponse(projectId=1, id=665721c002a02433, title=2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法, enTitle=Step-wise diagnostic approach for patients with uveitis - Experts consensus in Taiwan, guiderFrom=J Microbiol Immunol Infect, authorId=0, author=, summary=葡萄膜炎是一种威胁视力的眼部疾病，可由多种不同病因引起。葡萄膜炎的成功治疗主依赖准确诊断和有效治疗。本文主要提供了葡萄膜炎患者的分步诊断建议。, cover=https://img.medsci.cn/202242/1648870965801_1608702.jpg, journalId=0, articlesId=null, associationId=1043, associationName=中国眼科相关专家组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Fri Mar 18 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">葡萄膜炎是一种威胁视力的眼部疾病，可由多种不同病因引起。葡萄膜炎的成功治疗主依赖准确诊断和有效治疗。本文主要提供了葡萄膜炎患者的分步诊断建议。</span></p>, tagList=[TagDto(tagId=17700, tagName=葡萄膜炎)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=19556, appHits=124, showAppHits=0, pcHits=798, showPcHits=19432, likes=1, shares=25, comments=10, approvalStatus=1, publishedTime=Sat Apr 02 15:38:00 CST 2022, publishedTimeString=2022-03-18, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Sat Apr 02 11:44:00 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 01:36:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法.pdf)])
2022 中国台湾专家共识：葡萄膜炎患者的分步诊断方法.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1213978, encodeId=bb8612139e8a3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/9ea295fa6f1141baaf5cca7484a33164/749e6341395641abb4881b33ae5e9d68.jpg, createdBy=484e5725266, createdName=spiritnsy, createdTime=Sun Apr 24 21:32:52 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213850, encodeId=da2312138503b, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Sun Apr 24 10:19:14 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210141, encodeId=fdf41210141c3, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Sun Apr 10 22:08:41 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209962, encodeId=192712099629f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2883108677, createdName=4977194, createdTime=Sun Apr 10 07:44:48 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208782, encodeId=16b51208e8212, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Tue Apr 05 15:51:00 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-24 spiritnsy

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1213978, encodeId=bb8612139e8a3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/9ea295fa6f1141baaf5cca7484a33164/749e6341395641abb4881b33ae5e9d68.jpg, createdBy=484e5725266, createdName=spiritnsy, createdTime=Sun Apr 24 21:32:52 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213850, encodeId=da2312138503b, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Sun Apr 24 10:19:14 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210141, encodeId=fdf41210141c3, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Sun Apr 10 22:08:41 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209962, encodeId=192712099629f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2883108677, createdName=4977194, createdTime=Sun Apr 10 07:44:48 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208782, encodeId=16b51208e8212, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Tue Apr 05 15:51:00 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-24 眼科芳

    ***

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1213978, encodeId=bb8612139e8a3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/9ea295fa6f1141baaf5cca7484a33164/749e6341395641abb4881b33ae5e9d68.jpg, createdBy=484e5725266, createdName=spiritnsy, createdTime=Sun Apr 24 21:32:52 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213850, encodeId=da2312138503b, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Sun Apr 24 10:19:14 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210141, encodeId=fdf41210141c3, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Sun Apr 10 22:08:41 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209962, encodeId=192712099629f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2883108677, createdName=4977194, createdTime=Sun Apr 10 07:44:48 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208782, encodeId=16b51208e8212, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Tue Apr 05 15:51:00 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-10 349087

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1213978, encodeId=bb8612139e8a3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/9ea295fa6f1141baaf5cca7484a33164/749e6341395641abb4881b33ae5e9d68.jpg, createdBy=484e5725266, createdName=spiritnsy, createdTime=Sun Apr 24 21:32:52 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213850, encodeId=da2312138503b, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Sun Apr 24 10:19:14 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210141, encodeId=fdf41210141c3, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Sun Apr 10 22:08:41 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209962, encodeId=192712099629f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2883108677, createdName=4977194, createdTime=Sun Apr 10 07:44:48 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208782, encodeId=16b51208e8212, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Tue Apr 05 15:51:00 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-10 4977194

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1213978, encodeId=bb8612139e8a3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211121/9ea295fa6f1141baaf5cca7484a33164/749e6341395641abb4881b33ae5e9d68.jpg, createdBy=484e5725266, createdName=spiritnsy, createdTime=Sun Apr 24 21:32:52 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213850, encodeId=da2312138503b, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Sun Apr 24 10:19:14 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210141, encodeId=fdf41210141c3, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Sun Apr 10 22:08:41 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209962, encodeId=192712099629f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2883108677, createdName=4977194, createdTime=Sun Apr 10 07:44:48 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208782, encodeId=16b51208e8212, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a25466306, createdName=349087, createdTime=Tue Apr 05 15:51:00 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-05 349087

    学习

    0

相关指南

中国葡萄膜炎诊疗中眼内液检测专家共识（2020年）

中华医学会眼科学分会 · 2020-09-20

2019 ACR/AF指南：幼年特发性关节炎相关性葡萄膜炎的筛查，监测和治疗

美国风湿病学会(ACR,American College of Rheumatology) · 2019-04-25

2018 欧洲共识建议：少年特发性关节炎相关性葡萄膜炎的管理

国外风湿免疫科相关专家小组 · 2018-03-28